Biosimilars are expected to become a significant piece of the generics business worldwide, and Alvogen is spending $250 million to build a facility in Iceland to develop and manufacture biosimilars.
As of last year, biotech products accounted for 71% of the revenue generated by the top 10 pharmaceutical-biotech products, according to a new report from the Tufts Center for the Study of Drug Development.
Daniel Galbraith By Daniel Galbraith 2013 was a landmark year for the development of biosimilars. With the global acceptance of biosimilars--also called "follow-on biologics" or...
When Roche bought Genentech in 2009, it swelled its biologics production footprint, but it was unsure whether biosimilar completion would leave it with excess capacity. The doubt prompted Roche to shutter a Genentech cell culture facility before it ever produced a drug, a decision it is now overturning.
DSM Pharmaceutical Products had lined up a client for its new biologics plant in Australia even ahead of it opening. But as it officially goes online, it has added yet another deal to the roster.
St. Louis, MO-based Sigma-Aldrich's SAFC custom manufacturing business is making investments that will lead to commercial-scale antibody drug conjugates manufacturing at a facility in St. Louis.
There has been a big rush towards biologics manufacturing as drugmakers prepare for the new drugs that are becoming a larger piece of their portfolios. Swiss drugmaker Roche say it has 39 biologics in development.
Another contract manufacturer, seeing the growth in biologic drugs, is putting capital into capacity to capture more of that market. Sweden-based Recipharm will make a significant investment to expand its freeze-drying capabilities at a plant in Germany.
With biologic drugs making up a growing percentage of drug sales, more drugmakers are opening biologics plants worldwide. German equipment maker Sartorius Stedim Biotech hopes to tap deeper into that growth with a €33 million ($44.8 million) deal to buy TAP Biosystems.
With a $10.4 million contract from the Defense Advanced Research Projects Agency (DARPA), researchers at MIT hope to develop a process that would allow for super-fast production of biologic drugs in battlefield situations.